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ABSTRACT 24 
 25 
Decreased rates of transmission of transmissible spongiform encephalopathies (TSEs) to 26 
sheep have been attributed to some polymorphisms of the prion protein (PrP) and to a “species 27 
barrier” on inter-species experiments. In addition, the blood brain barrier may be a further 28 
impediment to TSE neuroinvasion. The intracerebral (I/C) route is generally considered the most 29 
efficient for TSE transmission, as it may help to by-pass those factors. Therefore, susceptibility of 30 
particular species to specific TSE agents are conducted by this route.  31 
Aims: This study (1) characterises the traumatic brain lesions associated with the I/C 32 
injection of the bovine spongiform encephalopathy agent in sheep, (2) assesses the relevance of 33 
such lesions in the outcome of clinical disease, and (3) provides insight into the mechanisms of PrPd 34 
conversion and amplification following I/C challenge.  35 
Methods: A total of 27 hemi-brains have been macroscopically and 36 
immunohistochemically examined to investigate the presence of lesions compatible with the needle 37 
track and the PrPd distribution, respectively.  38 
Results: No residual inoculum was found and the extension and severity of the traumatic 39 
brain lesions were unrelated to the clinical outcome. Sheep with PrPd accumulation in the brain also 40 
showed conspicuous focal aggregates in the porencephalic lesions and in the circumventricular 41 
organs. In contrast, sheep without PrPd deposits in the brain were also negative in the traumatic 42 
lesions.  43 
Conclusion: Overall these findings suggest that the efficiency of the I/C route is due to 44 
effective absorption and blood re-circulation of infection, rather than to primary amplification at the 45 
site of injection. 46 
 47 
Key words: Sheep, intracerebral, porencephalia, residual inoculum, prion protein 48 
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INTRODUCTION 49 
 50 
Transmissible spongiform encephalopathies (TSEs) of humans and several animal species 51 
are characterized by the abnormal post-transcriptional conversion of the cellular prion protein (PrPc) 52 
into a partially protease-resistant (PrPres) and disease-associated isoform (PrPd), which accumulates 53 
in the brain and is associated with neurodegeneration and onset of neurological signs. Sheep are 54 
experimentally susceptible to TSEs following challenge by a variety of routes of inoculation. These 55 
include oral [1,2,3], subcutaneous [4], dermal or ocular scarification [5], intralingual [6], 56 
conjunctival, intranasal and intraperitoneal [7], intravenous [8, 9, 10], and intracerebral [(I/C) 2,11] 57 
routes. However, the efficiency of these different routes is not the same, the I/C route being the one 58 
widely considered as the most efficient based on: 1) higher attack rates and shorter incubation 59 
periods than those observed by most other routes when sheep of the same PrP genotype are 60 
compared, even if the dose is lower for intracerebrally inoculated animals [2,6,7,11], 2) induction of 61 
lesions and even clinical disease in sheep of resistant ARR/ARR [12], or semi-resistant ARQ/ARR 62 
(N. Hunter, unpublished observations) genotypes, and 3) higher magnitude of accumulation and 63 
wider distribution of PrPd in the brain [11]. These last authors reported that sheep I/C challenged 64 
with the bovine spongiform encephalopathy (BSE) agent accumulated more PrPd in forebrain areas 65 
(frontal cerebral cortex and striatum) than did orally or intravenously inoculated ones, and 66 
hypothesized that this could respond to the proximity of these areas to the injection site. 67 
 68 
In the course of a large experiment [12] aiming to determine the susceptibility of sheep of 69 
different breeds and PrP genotypes to I/C challenge with the BSE agent, and as a result of the 70 
routine pathological examinations undertaken, focal areas of cavitation or porencephaly were 71 
detected in the cerebral cortex of the right brain hemisphere of a few sheep. Because of their 72 
location, they were considered to result from the experimental injection procedure. In sheep 73 
showing widespread PrPd accumulation in the brain these areas were also strongly positive for PrPd 74 
in immunohistochemistry (IHC). Thus, it was considered that infectivity could spread from these 75 
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sites and account for the differences previously observed in PrPd distribution [11] and progressive 76 
accumulation [13] between sheep challenged I/C and by other routes. Therefore, detailed 77 
examinations were carried out in the brains of 27 sheep in order to 1) characterize the pathological 78 
features of those injection-induced lesions and determine their prevalence after I/C challenge, 2) 79 
assess their influence on the generalization of PrPd accumulation in the brain and the outcome of 80 
clinical signs, and 3) gain insight on the pathogenetic mechanisms that make I/C challenge more 81 
efficient than other oral or parenteral infections. 82 
 83 
 84 
MATERIALS and METHODS  85 
The animals included in this study belonged to an experiment briefly described previously 86 
[12], in which 87 sheep of three different breeds (Suffolk, Cheviot and Poll-Dorset) and six PrP 87 
genotypes (ARQ/ARQ, ARQ/ARR, ARR/ARR, VRQ/VRQ, VRQ/ARQ and VRQ/ARR, where 88 
polymorphisms are indicated by the amino acid single letter code at codons 136, 154 and 171) were 89 
I/C challenged with 0.05g of cattle BSE brain homogenate into the right forebrain, following the 90 
procedure described by Foster et al. [1]. The experiments were reviewed and approved by the 91 
appropriate Ethical Review Committee and carried out under a current Home Office Licence. Sheep 92 
were closely monitored for neurological signs and euthanized once clinical disease was evident; 93 
some of the infected sheep died from intercurrent conditions and some others were culled at the end 94 
of the experiment -between 2,200 and 2,500 days post-inoculation- in the absence of clinical signs 95 
of TSE. Details of the patterns and neuroanatomical distribution of PrPd in the brains of clinically 96 
affected sheep from this experiment have been described previously [11]. Brains were removed at 97 
post-mortem, sliced sagitally, and one hemi-brain immediately immersed in formaldehyde. In the 98 
present study, a total of 27 fixed hemi-brains were macroscopically assessed for the presence of 99 
traumatic lesions compatible with the needle track by examining transversal sections of frontal, 100 
temporal and occipital cortices; 22 of the examined cases corresponded to the inoculated right 101 
hemi-brains and 5 to the contra-lateral non-inoculated hemi-brain. In addition, representative 102 
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sections of other brain areas (corpus striatum, thalamus/hypothalamus, midbrain, cerebellar vermis, 103 
and medulla oblongata at the obex) and of circumventricular organs [(CVOs) 13] were trimmed, 104 
embedded in paraffin-wax, and processed for histology and IHC examinations in order to 1) 105 
characterize the histological appearance and assess the extension of the lesions caused by the 106 
injection, and 2) determine the correlation between deposition of PrPd in those lesions, in the brain 107 
parenchyma and in the CVOs.  108 
 109 
Serial sections of those tissue specimens in which injection-derived lesions were observed 110 
after routine histological examinations were stained or immunolabelled by: 111 
 112 
- a modified Van Gieson staining technique (Merck KGaA, Darmstadt, Germany) to highlight 113 
collagen and elastic fibres that could be part of the scarring process and  neovascularization. Briefly, 114 
sections were immersed in Miller’s elastic stain solution for 1h, rinsed in running tap water for 2 115 
min and immersed in Weigert’s solution for 5 min. After another 2 min rinse, picrofuchsin solution 116 
was applied for 2 min. 117 
 118 
- a Pearl’s Prussian blue method in order to ascertain the presence of hemosiderin. Briefly, sections 119 
were immersed in acid ferrocyanide solution for 30mins, rinsed in 3 changes of distilled water and 120 
then counterstained in 0.5% neutral red for 2 minutes. 121 
  122 
- a luxol fast blue technique in order to assess the severity of myelin loss. Briefly, sections were 123 
immersed in 95%ethanol immediately removed and incubated at 60°C for 2 hours in luxol fast blue 124 
solution then quickly washed in70% ethanol followed by differentiation in 0.05% lithium carbonate 125 
then 95% ethanol and counterstained in cresyl fast violet. Sections were then differentiated in cresyl 126 
violet. 127 
 128 
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- an immunohistochemical (IHC) method according to the protocol described by González et al. 129 
[13] which aims to detect the disease-associated prion protein (PrPd) –a form of the prion 130 
protein partially protease-sensitive but not found in uninfected animals and therefore 131 
different from PrPres or PrPc, respectively. For that purpose, slides were incubated overnight 132 
at 24°C with R145 PrP rat monoclonal antibody (VLA Weybridge, UK, 1:4000 dilution) following 133 
antigen retrieval by immersion in 98% formic acid for 15 min at 24°C and autoclaving in 0.2% 134 
citrate buffer (pH 6.2) at 121°C for 30 min. The IHC procedure was completed by an 135 
immunoperoxidase method (Vector-elite ABC kit; Vector Laboratories, Peterborough, UK) with 136 
DAB (Sigma-Aldrich Company Ltd, Gillingham, UK) as a substrate, and sections were finally 137 
counterstained with Mayer’s haematoxylin. The magnitude of PrPd accumulation was subjectively 138 
scored from 0 to 3 in each of the neuroanatomical sites above mentioned –focal traumatic lesions, 139 
CVOs and representative areas of the brain parenchyma-, by methods reported previously [11, 13, 140 
14]. The topographical distribution of PrPd was assessed for each animal. 141 
 142 
- an IHC method with Z0334 polyclonal GFAP antibody (Dako, Ely, UK, 1:8000 dilution), to 143 
reveal astrocyte proliferation in association with the needle track lesion, by the same IHC protocol 144 
as for PrPd. 145 
 146 
- an IHC method with M0718 monoclonal CD68 antibody (Dako, 1:400 dilution), to investigate the 147 
eventual involvement of macrophages and activated microglia, by the same IHC protocol as for 148 
PrPd with the exception of the antigen retrieval; this was performed by immersion of sections in 149 
0.25% trypsin/αchymotrypsin 1/1 v/v, pH7.8 (Sigma) for 5 minutes at 37°C, followed by washing 150 
in 3 changes of PBST and rinsing in running tap water for 10 minutes.   151 
 152 
- a double IHC method for PrPd with antibodies KG9 (IAH, Compton, UK, 1:4000), which 153 
recognises bovine but not ovine PrP, and Bar224 (CEA, Saclay, France, 1:32000), which recognises 154 
ovine but not bovine PrP. This double immunolabelling approach aimed to achieve differentiation 155 
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between residual cattle BSE inoculum and  “de novo” converted ovine PrPd, and to compare PrPd 156 
patterns and distribution at the injection site with those obtained in sections labelled with R145, 157 
which recognises both sheep and cattle PrPd. The procedure was basically the same as for single 158 
IHC with R145: sections were incubated first overnight with KG9 antibody and developed with 159 
DAB substrate (brown), and then incubated for 1 hour with Bar224 and developed with VIP 160 
substrate (purple). Double IHC was also performed for GFAP and PrPd by incubating sections 161 
overnight with Z0334 antibody (developed with DAB), followed by 1 hour incubation with R145 162 
(developed with VIP).  163 
  164 
Sections from positive-control and negative-control tissue blocks were included in each 165 
IHC run to ensure consistency in the sensitivity and specificity of the IHC procedure, respectively. 166 
In addition, the specificity of the PrPd immunodeposits observed at the injection-induced lesions 167 
was reassessed by incubating sections without the primary antibody or with a rat immunoglobulin 168 
of the same IgG1 isotype as R145. At the end of all staining or IHC procedures sections were 169 
dehydrated and mounted by routine procedures. 170 
 171 
 172 
RESULTS 173 
 174 
Occurrence and characteristics of the traumatic lesions resulting from the intracerebral 175 
injection 176 
 177 
Gross lesions compatible with needle injury were observed in 15 out of 22 sheep in which 178 
the right hemi-brain was examined (Table 1). The contra-lateral, left hemi-brain was examined in a 179 
further 5 sheep, and no such lesions were observed. For sheep in which right hemi-brains were 180 
examined, those showing traumatic lesions were of three different breeds: Cheviot (1/4), Poll-181 
Dorset (4/6) and Suffolk (10/12), and three different PRNP genotypes: ARQ/ARR (10/11), 182 
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ARR/ARR (4/7), and VRQ/VRQ (1/1); no such lesions were found in the right hemi-brain from one 183 
ARQ/ARQ and two VRQ/ARR animals. Lesions consisted of a single elongated cyst of 184 
approximately 0.5-1cm length and 1-2mm width in the frontal aspect of the anterior lateral gyrus, 185 
mainly in the transition between grey and white matter (Figure 1). In seven cases, cavities extended 186 
from frontal to temporal cortical areas, and more occasionally involved the internal capsule (Table 187 
1). 188 
 189 
The needle injury within the brain did not appear to result in permanent overt clinical 190 
disease, as 11 out of 15 cases showing such lesions in the cerebral cortices were culled at the end of 191 
the experiment, around six-and-half years after inoculation, in the absence of clinical signs (Table 192 
1). This is not surprising if we consider the small extent of the traumatic lesions, their location 193 
within the cerebral cortex, and the absence of inflammatory changes that could have resulted from 194 
needle contamination.  195 
 196 
Haematoxylin-eosin stained sections showed rarefaction of grey matter and pallor of white 197 
matter surrounding cortical cavities; myelin loss was confirmed in the latter in luxol fast blue-198 
stained sections (Figure 1). In most cases, lesions appeared as cysts partially filled with round cells 199 
of abundant cytoplasm containing yellow to brownish-orange granules of apparent blood 200 
breakdown products (Figure 1); they were confirmed as haemosiderin-loaded macrophages, as they 201 
showed CD68-positive reaction and the granules were positive in the Pearl’s Prussian blue stain. 202 
The cavities were delimited by a repair or scarring tissue formed by GFAP-positive fibrillary 203 
astrocytes and sparse microglial cells, in which marked proliferation of swollen neo-capillaries was 204 
observed (Figure 1). Numerous GFAP-positive but CD68-negative cells containing haemosiderin 205 
(Figure 1) were common in this repair tissue and in cortical grey matter areas adjacent to the cystic 206 
lesion, indicating that astrocytes were also involved in phagocytic removal of extravasated red 207 
blood cells. 208 
 209 
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Overall, the appearance of the lesions and the reactive changes were suggestive of an 210 
original vascular insult leading to focal haemorrhage. In a few cases with no grossly apparent 211 
porencephalia or little cavitation, a severe reactive fibrillary astrocytosis completely or almost 212 
completely repaired the old cavitating lesion (Figure 1). Exceptionally, severe fibrosis of the 213 
meningeal stroma similar to repair granulation tissue was revealed by Van Gieson staining; in these 214 
cases the needle appeared to have caused severe meningeal damage, although meningitis was never 215 
observed.  216 
 217 
Deposition of PrPd associated with the traumatic lesions, the CVOs and elsewhere in the brain  218 
 219 
As shown in table 1, in four of 15 cases in which traumatic lesions were found, PrPd was 220 
absent both in the injection-induced cystic area and in the rest of the brain parenchyma. Three of 221 
these were of the ARR/ARR PrP genotype and one was ARQ/ARR; none of them had shown signs 222 
of disease. 223 
 224 
In three sheep (two ARQ/ARR and one ARR/ARR sheep) without PrPd accumulation in 225 
any other area of the brain parenchyma, intracellular, single or multiple R145-positive granules 226 
restricted to the periphery of the cystic lesion were observed. Those granules were also 227 
immunolabelled, albeit more faintly, with Bar224 (Figure 2). Omission of the primary PrP antibody 228 
or substitution by a rat IgG1 (Figure 2) resulted in loss of such granular labelling; these granular 229 
deposits were therefore interpreted as PrP-specific. Double immunolabelling was used to 230 
discriminate between PrP of cattle origin (using KG9) and that of sheep origin (using Bar224). No 231 
labelling was observed with KG9 antibody indicating an absence of cattle derived PrPd  from the 232 
inoculum. However, using the Bar224 antibody, PrPd was recognised within the granules  233 
indicating local de novo generation of ovine PrPd . In order to ascertain the association between 234 
those granular PrP-immunoreactive deposits and the experimental BSE challenge, tissue samples 235 
with similar porencephalic lesions were sourced from archive cases of non-TSE conditions, such as 236 
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swayback or chronic polyoencephalomalacia. Immunolabelling of such sections with R145 and 237 
Bar224 showed similar PrP positive granules (data not shown).     238 
 239 
 Finally, in another eight of those 15 cases, PrPd immunodeposits, positive with R145 or 240 
Bar224 but negative with KG9 were present both in the traumatic lesion and in several other areas 241 
of the brain confirming again that PrPd as no residual inoculum (cattle BSE) . Accumulation of PrPd 242 
in the porencpehalic lesions varied from mild deposits restricted to the margins of the cysts, shown 243 
by double IHC to be often associated with fibrillary astrocytes, to prominent, sometimes plaque-like 244 
aggregates in the repair tissue surrounding the traumatic lesion, which appear to spread along white 245 
matter tracts to neighbouring areas of the cerebral cortex (Figure 2) and even to the internal capsule. 246 
The amount of PrPd in the focal traumatic lesions appeared to be related to the extent or severity of 247 
the lesion itself rather than to the total magnitude of PrPd accumulation in the whole of the brain. 248 
However, accumulation of PrPd in the cerebral cortex of right hemispheres showing traumatic 249 
lesions was more prominent than in those hemi-brains, either right or left, without evidence of 250 
traumatic lesion (Table 1, figure 3). As far as deposition in brainstem areas and cerebellum is 251 
concerned, right hemi-brains without discernible traumatic lesions (n=7) and left hemi-brains (n=5), 252 
showed a magnitude and distribution of PrPd that was similar to that observed in right hemi-brains 253 
in which injection-derived cystic lesions were found (Figure 3). Altogether, these findings suggest 254 
that PrPd accumulated specifically in association with the traumatic lesions when these persisted 255 
after intracerebral inoculation, in those cases in which generalized PrPd aggregates were also 256 
present, and that infection spread from those focal lesions to neighbouring forebrain areas. As 257 
shown in table 1 and figure 4, all PrPd-positive sheep showed widespread and marked 258 
immunoreactivity in the CVOs, even in those cases where the total PrPd magnitude in the brain was 259 
low. 260 
 261 
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Lack of intracellular immunolabelling with the P4 monoclonal antibody [3] confirmed that 262 
all generated PrPd, either in the traumatic lesion or in the brain parenchyma, was of the BSE 263 
characteristics (data not shown). 264 
 265 
 266 
DISCUSSION 267 
 268 
Sheep with long incubation periods or culled at the end of the experiment were deliberately 269 
selected for this study in order to ascertain the persistence of traumatic lesions associated with I/C 270 
injection. As expected, most of them were of PRNP genotypes associated with resistance to 271 
infection by the oral route [2] and with relatively low susceptibility by the I/C route (N. Hunter, 272 
unpublished observations). Also, they mostly showed low overall magnitudes of PrPd in the brain, 273 
even if clinically affected as previously described [11], which allowed comparison between the 274 
amounts of PrPd deposited in the traumatic lesions, in the CVOs, and elsewhere in the brain 275 
parenchyma. 276 
 277 
As no significant clinical signs were reported immediately after challenge, the initial 278 
lesions probably resulted in minimal oedema and increased intracranial pressure. Focal cavities or 279 
cysts persisted for years and were presumably stable in the cerebral cortex of some sheep after I/C 280 
injection of BSE. The fact that those focal lesions were not discernible in some other sheep 281 
subjected to the same inoculation procedure, indicates variability in the damage initially caused: in 282 
some cases such damage would be insignificant and readily healed, while in other cases, accidental 283 
puncture of blood vessels would lead to focal haemorrhage followed by a slow, incomplete and 284 
imperfect repair. The presence of haemosiderin-loaded macrophages and astrocytes argues for an 285 
initial vascular damage followed by a macrophage-associated removal of erythrocytes and later by 286 
reactive astrogliosis and neovascularisation. It seems clear from the results here presented that these 287 
porencephalic lesions, even when they persist, have no long-term repercussion for neurological 288 
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disease, probably because of the limited size of the cavities formed and their location within the 289 
cerebral cortex. In fact, sheep with no discernible traumatic lesions in the cerebral cortex displayed 290 
more commonly neurological signs with generally shorter incubation periods, even though they 291 
accumulated less PrPd, not only in forebrain areas but also elsewhere, than sheep with 292 
porencephalic lesions (Table 1).  293 
 294 
The second point addressed by this study was the potential impact of the traumatic cerebral 295 
lesions on the efficiency of the I/C route of infection and on the relatively distinct PrPd distribution 296 
after I/C inoculation when compared to other routes. It has been reported that, in oral scrapie and 297 
BSE transmissions to sheep, PrPd progressively accumulates in the brain in a caudo-rostral manner, 298 
with early involvement of the dorsal motor nucleus of the vagus and of the CVOs, and relatively 299 
late involvement of forebrain areas in pre-clinically affected animals [13]. PrPd deposition was also 300 
less severe in the frontal cerebral cortex and corpus striatum of clinically affected BSE-infected 301 
animals when challenged by the oral or intra-venous routes [11]. In contrast, sheep inoculated with 302 
BSE by the intracerebral route, either in pre-clinical stage [13] or clinically affected [11] showed 303 
an earlier or more severe involvement of forebrain areas, respectively. We believe that those 304 
differences are the result of the focal injury, as PrPd accumulation in the forebrain was less 305 
pronounced in those sheep in which focal traumatic lesions were not discernible, or when 306 
examining the contra-lateral, left brain hemisphere, while PrPd depositions in other areas like 307 
thalamus, brainstem or cerebellum were bilaterally distributed (Figure 3). However, focal 308 
accumulation of PrPd in the injection-derived lesions and its further spread to neighbouring areas of 309 
the brain do not appear to result from primary conversion of inoculum-derived PrPd at the site of 310 
injection. Thus, remains of the cattle-derived inoculum were not detected in those lesions. Also, 311 
sheep that did not show PrPd accumulation elsewhere in the brain were also negative in the focal 312 
traumatic lesions, and the magnitude of PrPd accumulation in those lesions, when it occurred, was 313 
never significantly higher than in the whole of the brain. Furthermore, sheep of the same breed and 314 
PRNP genotype could develop moderate to severe PrPd accumulation in the brain, and even clinical 315 
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signs, in the absence of discernible traumatic lesions. These findings do not support the notion that 316 
generalized PrPd accumulation in the brain of I/C infected sheep arises from extension of primary 317 
conversion at the inoculation site. 318 
 319 
More problematic to interpret are the intracellular PrP granules observed at the periphery of 320 
cysts of three sheep, in which no PrPd deposition was found elsewhere in the brain (Figure 2). Once 321 
their residual bovine inoculum origin is eliminated, two alternative hypothesis can be proposed: 1) 322 
that they originated from early and inefficient in situ conversion of ovine PrPc into PrPd, which was 323 
latter phagocytised by reactive macrophages and astrocytes, or 2) that they correspond to 324 
endocytosed PrPc, following its earlier focal over-expression as a result of the traumatic injury. The 325 
facts that our IHC protocol for PrPd did not include enzymatic pre-treatment (i.e. digestion with 326 
proteases), the findings of PrPc upregulation in hypoxic human brains with no associated prion 327 
pathology [15], and the detection of similar immunoreactive granules in cerebral cortices of sheep 328 
with chronic porencephalic lesions unrelated to prion disorders support this second possibility. 329 
 330 
We therefore postulate that after intracerebral inoculation with BSE-infected brain material, 331 
the inoculum (cattle BSE) is reabsorbed before any conversion in situ takes place, circulates in the 332 
cerebrospinal fluid (CSF) and is drained to the blood stream through the dural venous sinuses 333 
and/or to the lymphatic system through the cribriform plate, following the lymphatic cerebrospinal 334 
and interstitial fluids absorption pathways [16, 17]. Once in the circulatory system, infectivity 335 
would again reach the brain by portals of entry such as the CVOs [13]. However, because of the 336 
rich and fenestrated neovascularization [18] of the repaired focal traumatic lesions, or because of 337 
their intimate contact with CSF from meningeal wounds, infectivity will also gain rapid access to 338 
those lesions, resulting in focal accumulation of PrPd and later spread to related forebrain areas. The 339 
consistent and conspicuous PrPd deposits observed in the CVOs –which also have fenestrated 340 
capillaries- of these same sheep argues in favour of this hypothesis. It remains to be elucidated if a 341 
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local up-regulation of PrPc, as a result of the traumatic and vascular insult, contributes to the focal 342 
accumulation of PrPd in the porencephalic areas. 343 
 344 
 This notion of rapid absorption of the intracerebral inoculum is in agreement with the 345 
findings of Hamir et al. [19], in I/C scrapie-infected sheep. These authors found similar lesions in 346 
association with the injection, though more of an acute nature, as sheep were killed shortly after 347 
inoculation; residual inoculum was detected up to three days post-inoculation, but not for the 348 
following six weeks. Similarly, no PrPres or infectivity were detected in the brain of mice inoculated 349 
with the agent of Creutzfeldt-Jakob disease during a four-week post-inoculation period, which was 350 
attributed to rapid absorption of the inoculated material [20]. It has been noticed for viruses, that 351 
both strain and dose at the site of inoculation have an influence on the rate of viral transport through 352 
neural circuitry [21]. It is plausible then that after a high dose I/C inoculation, cells at the site of 353 
inoculation are the initial site at which infectivity is established. However, such a neural circuitry 354 
hypothesis following the needle puncture could not explain how PrPd deposition in extra-cortical 355 
brain areas remained bilateral and symmetrical. According to the recently described role of the 356 
CVOs as portal of entry of TSE agents in the brain of sheep [13], it looks more plausible that PrPd 357 
from the inoculum in these animals is reabsorbed, ending in the CSF, lymph and/or blood to re-358 
enter the brain through the blood supply, CSF and CVOs.  359 
 360 
According to this hypothesis of blood recirculation of infectivity after I/C injection, other 361 
routes of infection should be as efficient as the I/C. Indeed, Hamir et al. [6] have reported similar 362 
efficiency of the I/C and the intralingual routes, although in this case, rapid access of the infectious 363 
agent via nerves could not be excluded. Although proper comparisons between the I/C and the 364 
intravenous routes have not been performed, results of a recent blood transfusion experiment [14] 365 
indicated that the intravenous route is more efficient than oral dosing. In that experiment, five 366 
ARQ/AHQ sheep dosed orally with cattle BSE did not show any evidence of PrPd accumulation in 367 
any tissue when culled 300-400 days post-dosing, whereas another five sheep of the same genotype 368 
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developed clinical disease at around 700 dpi, when infected intravenously with a lower dose of the 369 
same inoculum. This incubation period is just slightly longer than that observed after intracerebral 370 
injection of cattle BSE in sheep of a more susceptible ARQ/ARQ genotype, which is readily 371 
infected by the oral route [11]. 372 
  373 
Therefore, these observations suggest that the dogma of the I/C route being the most 374 
efficient, and the reasons of its efficacy in terms of lesion severity and incubation period, have to be 375 
re-considered. Improved efficacy of the I/C route reported previously may be connected more to 376 
rapid and efficient delivery of infectivity to blood circulation, rather than to accelerated local 377 
replication and avoidance of the immune system, as originally suggested [22,23].  378 
 379 
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Table 1. Details of the sheep examined, the occurrence of porencephalic lesions associated 452 
with the needle injury, and the accumulation of PrPd in those lesions and elsewhere in the 453 
brain.  454 
Sheep   PM  Traumatic lesion  PrPd in 
ID No Breed Genotype  DPI CS Location PrPd Forebrain Brain CVOs 
C533 Suffolk ARQ/ARR   2275 N  F/T PrPc  0 0 0 
D671 Suffolk ARR/ARR  2241 N T PrPc 0 0 0 
D552 Cheviot ARQ/ARR  2151 N F/T PrPc 0 0 0 
C422 Suffolk ARQ/ARR  1744 N F 0 0 0 0 
C397 Suffolk ARR/ARR  1233 N T 0 0 0 0 
C427 Suffolk ARR/ARR  2418 N T 0 0 0 0 
4271 Suffolk ARR/ARR  2418 N F 0 0 0 0 
        2069        0 0   
D76 P. Dorset ARQ/ARR  2179 Y F/T/S 1.5 3 13 3/3 
D160 P. Dorset ARQ/ARR  2241 N F/T 1.5 2 10.5 5/5 
D183 P. Dorset ARQ/ARR  2244 N F/T 2.5 1.5 10 6/6 
H155 P. Dorset VRQ/VRQ  1085 Y F 0.5 3 10.5 6/6 
C525 Suffolk ARQ/ARR  1976 Y F 0.5 2.5 13 3/3 
C524 Suffolk ARQ/ARR  2017 Y F/S 0.2 0.7 7.4 2/2 
C514 Suffolk ARQ/ARR  2274 N F 1 2 9 6/6 
C508 Suffolk ARQ/ARR   2275 N  F/T 2  2.5 12 6/6 
        2036        3.3 14.5   
F26 Cheviot ARR/ARR  1105 Y nf R na 0.2 4 1/1 
F13 Cheviot ARR/ARR  1576 Y nf R na 0.7 5.7 2/2 
D450 Cheviot VRQ/ARR  1843 Y nf R na 0.7 3.7 1/1 
D252 P-Dorset ARQ/ARR  1924 Y nf R na 0 2.2 2/2 
D693 Suffolk ARR/ARR  2299 Y nf R na 2 9 5/5 
C352 Suffolk ARQ/ARQ  2414 N nf R na 0 1.2 4/4 
F308 P-Dorset VRQ/ARR   2522 N  nf R na  0 0.4 0/2 
        1955        0.72* 4.92*   
F175 Cheviot ARR/ARR  1108 Y nf L na 0.4 5.9 1/1 
C29 P-Dorset ARR/ARR  1248 Y nf L na 1.5 8.5 5/5 
F22 Cheviot ARR/ARR  1473 Y nf L na 1.2 9.7 4/4 
C425 Suffolk ARR/ARR  1557 Y nf L na 2 10.5 5/5 
C346 Suffolk ARR/ARR  1008 Y nf L na 1.5 9 2/2 
        1279        1.6 8.7   
 455 
ID No, sheep identification number; PM, at post-mortem; DPI, days post-inoculation; CS, clinical 456 
signs; F, frontal cortex; T, parieto-temporal cortex; S, corpus striatum; Y, yes. N, no; nf, not found; 457 
R, right hemibrain; L, left hemibrain; na, not applicable. Averages shown in bold for DPI, PrPd 458 
magnitude in forebrain and in the whole brain. *Average score for clinically-affected sheep only; 459 
note that hemibrains with focal traumatic lesions showed proportionally higher magnitude of PrPd 460 
accumulation in forebrain with respect to the whole brain (23%) than right hemibrains without 461 
Porencephalia after intracerebral BSE  
 
- 20 - 
traumatic lesions (17%). Fractions within the CVO column show the number of positive CVOs out 462 
of the number examined.  463 
 464 
Figure 1. Characteristics of the lesions induced by the needle in the cerebral cortex. Lesions 465 
(green arrow) could be grossly identified as small cavities in the right cerebral cortex at the 466 
transition between white and grey matter of the anterior lateral gyrus (A; 1, sulcus splenialis; 2, 467 
sulcus lateralis). Histologically, needle-induced lesions appeared as areas of white matter 468 
rarefaction (B; haematoxylin and eosin [H-E] x10) or cystic cavities between the white and grey 469 
matter (C; H-E x2), in which macrophages filled with hemosiderin-like granules were observed (C 470 
inset; H-E x60). Moderate to severe myelin loss was associated with the porencephalic lesion (D; 471 
luxol fast blue x4). The repair tissue surrounding the cysts consisted mostly of proliferation of neo-472 
capillaries (E; Van Gieson x4) and reactive astrocytes (F; GFAP x10). In some cases, the traumatic 473 
lesions were almost healed by the repair tissue (G; H-E x4). GFAP-positive protoplasmic astrocytes 474 
were also present in the neighbouring grey matter (H; GFAP x20) and also contained hemosiderin 475 
(I, Pearl’s Prusian blue x 20).  476 
 477 
Figure 2.  Accumulation of PrPd in the traumatic lesions caused by the intracerebral injection. 478 
Most de novo created, sheep derived PrPd accumulated in the cerebral white matter, within or in 479 
close association with the repair tissue (A; IHC with R145 x4). PrPd immunodeposits varied in 480 
magnitude being occasionally very prominent and plaque-like (B; IHC with R145 x60) specially 481 
when associated with florid plaques (B inset; H-E x60). Reactive astrocytes forming part of the 482 
repair tissue also contained PrPd (C; double IHC for GFAP [brown] and with R145 [purple] x10; 483 
left inset x60). Over-expression of PrPc shown as brownish granules was observed in the focal 484 
traumatic lesions (D; IHC with R145 x20) of three sheep that did not show generalized PrPd 485 
accumulation in the brain; they were seldom intraneuronal (D; lower inset x20), and more 486 
frequently intra-astrocytic (D; upper inset x20); these granules were also labelled with another PrP 487 
antibody (E; IHC with Bar224 x60), but not with a rat IgG monoclonal (F; x60) or with KG9 PrP 488 
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antibody (G; x60).  The bluish-black cytoplasmic granules (F and G) represent pigment and not PrP 489 
immunoreactivity. 490 
  491 
Figure 3. Topographical distribution of PrPd accumulation in hemi-brains of sheep infected 492 
with cattle BSE by the intracerebral route. Right (R) forebrain areas of I/C challenged sheep 493 
with porencephalic lesions showed diffuse and more abundant PrPd deposits than did left hemi-494 
brains (L), while PrPd was symmetrically distributed in the diencephalon and brainstem. Note that 495 
PrPd accumulated in the site of injection (arrow). Colours indicate magnitude of PrPd accumulation 496 
in those areas: not coloured (0, absence), yellow (0-1, mild), orange (1-2, moderate), and red (2-3, 497 
severe). 498 
 499 
Figure 4. Immunolabelling of PrPd deposits in CVOs. An asterisk (*) highlights the specific 500 
location of the CVO when the picture has been captured at low magnification. AP, Area postrema, 501 
x2; PG, Pineal gland, x4; ME, Median eminence, x2; SCO, Subcommisural organ, x20; OVLT, 502 
Organum vasculosum of the lamina terminalis, x2; SFO, Subfornical organ, x2. Note the close 503 
proximity between some of the CVOs and the ventricles (III and IV), the Silvio’s aqueduct (SAq.), 504 
the dorsal motor nucleus of the vagus (DMNV), the optic nerve (ON), the fornix, the anterior white 505 
commisure (AWC) and the posterior white commisure (PWC). 506 
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